Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Broadchest aerosol for coronary microvascular disease
ChiCTR2300078090Phase 4Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Dec 2023
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of kuanxiong aerosol in Coronary Small Vessel Disease (CMD) (2 arms), sponsored by Xijing Hospital. Primary endpoint: Microcirculatory function. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
kuanxiong aerosol
03
Conditions
Coronary Small Vessel Disease (CMD)
Beyond the preview
Go deeper on ChiCTR2300078090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078090.